article thumbnail

The MEK effect on cancer — a slow and steady approach to drug resistance

PharmaVoice

This slow and steady concept gained more validation in June when the company announced early but promising data from a phase 2 trial of its MEK inhibitor atebimetinib combined with chemotherapy, which showed a six-month 94% overall survival in pancreatic cancer.

Immunity 130
article thumbnail

With ADCs on the rise, drugmakers embrace a new oncology pillar

PharmaVoice

At ASCO, one of the most talked-about studies was a late-stage trial in which the treatment outperformed chemotherapy as a first-line drug. As we move earlier, almost all of our trials will be in combination with different [immuno-oncology] drugs and … even chemotherapy drugs,” Keller said. “As

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers

Pharmacy Times

The findings of the DeLLphi-304 study demonstrated improved OS of tarlatamab compared with single-agent chemotherapy (median OS [mOS], 13.6 The updated definition for HRMM is increasingly important as there is an increased focus on how to improve outcomes for patients with HRMM, functional HRMM, and true extramedullary disease.

article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. For this application, the FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic.

article thumbnail

Toripalimab can fortify Dr. Reddy’s oncology portfolio as first checkpoint inhibitor for NPC in India: GlobalData

Express Pharma

In 2023, Dr. Reddy’s entered into a licensing and commercialization agreement with Shanghai Junshi Biosciences for toripalimab. The drug is also approved as a monotherapy for patients experiencing disease progression after platinum-based chemotherapy.

article thumbnail

Study Reveals Gaps in GINA Guideline Adherence for Asthma Treatment

Pharmacy Times

Study Overview Researchers conducted a retrospective chart review of 80 patients aged 12 or older within Intermountain Health who were diagnosed with asthma between December 2022 and December 2023. To ensure continuity of care, patients included had seen a primary care provider both in the year prior to and following their diagnosis.

article thumbnail

Pharmacies Need Strategies to Improve Health Care Access

Pharmacy Times

Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A. Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A.